Skip to main content
SpringerLink
Log in

Inhalative Kortikosteroide bei COPD

Einsatz kritisch überdenken

Inhaled corticosteroids in COPD

Critically consider administration

  • Journal Club
  • Published:
Der Pneumologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Brightling CE, Monteiro W, Ward R et al (2008) Sputum eosinophilia and short-therm response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356:1480–1485

    Article  Google Scholar 

  2. Dusser D, Bravo ML, Iacono P (2006) The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 27:547–555

    Article  CAS  PubMed  Google Scholar 

  3. Gibson PG, Fujimura M, Niimi A et al (2002) Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 57:178–182

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. GINA Executive and Science Committee (2014) Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention

  5. GOLD Executive Committee (2014) Global initiative for chronic obstructive lung disease. http://www.goldcopd.com

  6. Jarad NA, Wedzicha JA, Burge PS, Calverley PM (1999) An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 93:161–166

    Article  CAS  PubMed  Google Scholar 

  7. Kitaguchi Y, Komatsu Y, Fujimoto K et al (2012) Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 7:283–289

    PubMed Central  CAS  PubMed  Google Scholar 

  8. Liesker JJ, Bathoorn E, Postma DS et al (2011) Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med 105:1853–1860

    Article  PubMed  Google Scholar 

  9. Magnussen H, Disse B, Rodriguez-Roisin R et al (2014) Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371:1285–1294

    Article  PubMed  Google Scholar 

  10. Magnussen H, Watz H, Kirsten A et al (2014) Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir Med 108:593–599

    Article  PubMed  Google Scholar 

  11. Manoharan A, Short PM, Anderson WJ, Lipworth BJ (2014) Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. Lung 192:649–652

    Article  CAS  PubMed  Google Scholar 

  12. Nadeem NJ, Taylor SJ, Eldridge SM (2011) Withdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodology. Respir Res 12:107

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Valk P van der, Monninkhoff E, Palen V van der et al (2002) Effect of discontinuation of inhalaed corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 166:1358–1363

    Article  PubMed  Google Scholar 

  14. Vogelmeier C, Hederer B, Glaab T et al (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364:1093–1103

    Article  CAS  PubMed  Google Scholar 

  15. Wedzicha JA, Calverley PMA, Seemungal TAR et al (2008) The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177:19–26

    Article  CAS  PubMed  Google Scholar 

  16. Wouters EF, Postma DS, Fokkens B et al (2005) Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD cause immediate and sustained disease deterioation: a randomised controlled trial. Thorax 60:480–487

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. A. Gillissen hat von Boehringer Ingelheim Reisekosten und Honorare für Vorträge sowie von Chiesi, Teva und Novartis Reisekosten und Honorare für Vortrags- und Beratungsleistungen erhalten.

Author information

Authors and Affiliations

  1. Klinik für Lungen- und Bronchialmedizin, Klinikum Kassel, Mönchebergstr. 41–43, 34125, Kassel, Deutschland

    A. Gillissen

Authors
  1. A. Gillissen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Gillissen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gillissen, A. Inhalative Kortikosteroide bei COPD. Pneumologe 12, 140–143 (2015). https://doi.org/10.1007/s10405-014-0859-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-014-0859-8

Search

Navigation